

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptau153cxa

PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?):2

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America  
NEWS 5 AUG 30 CA/CAplus -Increased access to 19th century research documents  
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions  
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 8 SEP 22 MATHDI to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:22:12 ON 27 SEP 2005

=> file caplus uspatful japiro epfull medline biosis embase scisearch  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.84 0.84

FILE 'CAPLUS' ENTERED AT 15:24:34 ON 27 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:24:34 ON 27 SEP 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:24:34 ON 27 SEP 2005

COPYRIGHT (C) 2005 Japanese Patent Office (JPO) - JAPIO

FILE 'EPFULL' ENTERED AT 15:24:34 ON 27 SEP 2005

COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 15:24:34 ON 27 SEP 2005

FILE 'BIOSIS' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright (c) 2005 The Thomson Corporation

=> s mucositis and radiotherap? and (flavonoid# or isoflavonoid#)

L1 10 MUCOSITIS AND RADIOTHERAP? AND (FLAVONOID# OR ISOFLAVONOID#)

=> d 11 1-10 ibib abs

L1 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:855814 CAPLUS

DOCUMENT NUMBER: 139:333152

TITLE: Curcumin combination for the prevention and/or treatment of tissue damage

INVENTOR(S): Rezvani, Mohiaddin

PATENT ASSIGNEE(S): Isis Innovation Limited, UK

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIXXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088986	A1	20031030	WO 2003-GB1694	20030416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2387541	A1	20031022	GB 2002-8691	20020416
EP 1501526	A1	20050202	EP 2003-722760	20030416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			GB 2002-8691	A 20020416
			GB 2002-18412	A 20020808
			WO 2003-GB1694	W 20030416
AB	A combination of curcumin, an antioxidant, especially $\alpha$ -tocopherol, and at least one edible oil, especially sunflower oil, is useful in the prevention and/or treatment of tissue damage caused by non-phys. insult, especially mucositis or CNS damage caused by cancer therapy.			
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L1 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:84586 CAPLUS  
 DOCUMENT NUMBER: 132:127742  
 TITLE: Pharmaceutical composition in particular for preventing and treating **mucositis** induced by **radiotherapy** or chemotherapy comprising antiradical compounds  
 INVENTOR(S): Besse, Jerome; Nguyen, Tham; Leyder, Joelle  
 PATENT ASSIGNEE(S): Laboratoire L. Lafon, Fr.  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004878	A1	20000203	WO 1999-FR1760	19990719
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2781156	A1	20000121	FR 1998-9230	19980720
FR 2781156	B1	20010629		
CA 2337152	AA	20000203	CA 1999-2337152	19990719
AU 9946296	A1	20000214	AU 1999-46296	19990719
EP 1098631	A1	20010516	EP 1999-929503	19990719
EP 1098631	B1	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002521321	T2	20020716	JP 2000-560871	19990719
AT 235226	E	20030415	AT 1999-929503	19990719
PT 1098631	T	20030630	PT 1999-929503	19990719
ES 2196823	T3	20031216	ES 1999-929503	19990719
PRIORITY APPLN. INFO.:			FR 1998-9230	A 19980720
			WO 1999-FR1760	W 19990719

AB The invention concerns a pharmaceutical composition designed to adhere to a mucous membrane in particular for preventing or treating **radiotherapy**-related and chemotherapy-related **mucositis**, induced by **radiotherapy** or combined radiochemotherapy, comprising an efficient amount of an antiradical compound mixed with a vehicle which is liquid at room temperature and gels at the mucous membrane temperature and capable of adhering to the mucous membrane by its gelled state. A pharmaceutical composition for buccal mucosa contained hydrosol. rutoside 2-10, Poloxamer-407 14.0, HPMC 1-3, fragrance 0.1-0.5, and buffer for pH = 7 q.s. 100%.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 10 USPATFULL on STN  
 ACCESSION NUMBER: 2003:283125 USPATFULL  
 TITLE: Combination of bryostatin and paclitaxel for treating cancer  
 INVENTOR(S): Schwartz, Gary K., Briarcliff Manor, NY, UNITED STATES  
 Albino, Anthony P., New York, NY, UNITED STATES  
 PATENT ASSIGNEE(S): Sloan - Kettering Institute for Cancer Research (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199469	A1	20031023
APPLICATION INFO.:	US 2002-215178	A1	20020807 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-137442, filed on 20 Aug 1998, GRANTED, Pat. No. US 6444638 Continuation of Ser. No. WO 1997-US3341, filed on 20 Feb 1997, PENDING Continuation-in-part of Ser. No. US 1996-619304, filed on 21 Mar 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-603814, filed on 20 Feb 1996, GRANTED, Pat. No. US 5821072		

DOCUMENT TYPE:

Utility

FILE SEGMENT:

APPLICATION

LEGAL REPRESENTATIVE:

John P. White, Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036

NUMBER OF CLAIMS:

35

EXEMPLARY CLAIM:

1

NUMBER OF DRAWINGS:

12 Drawing Page(s)

LINE COUNT:

5326

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:271068 USPATFULL

TITLE: Use of metabolic phenotyping in individualized treatment with amonafide

INVENTOR(S): Leyland-Jones, Brian, Miami, FL, UNITED STATES

PATENT ASSIGNEE(S): McGill University, Montreal, CANADA (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003190671	A1	20031009
APPLICATION INFO.:	US 2002-124747	A1	20020416 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-87996, filed on 28 Feb 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271714P	20010228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	88	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	31 Drawing Page(s)	
LINE COUNT:	8446	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug, amonafide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:200394 USPATFULL

TITLE: Use of metabolic phenotyping in individualized treatment with amonafide

INVENTOR(S): Leyland-Jones, Brian, Miami, FL, UNITED STATES

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2003138377 A1 20030724

APPLICATION INFO.: US 2002-87996 A1 20020228 (10)

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 2001-271714P 20010228 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133

NUMBER OF CLAIMS: 88

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 29 Drawing Page(s)

LINE COUNT: 8181

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug, amonafide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2001:123568 USPATFULL

TITLE: COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS

INVENTOR(S): SCHWARTZ, GARY K., BRIARCLIFF MANOR, NY, United States ALBINO, ANTHONY P., NEW YORK, NY, United States

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2001011076 A1 20010802

US 6444638 B2 20020903

APPLICATION INFO.: US 1998-137442 A1 19980820 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1997-US3341, filed on 20 Feb 1997, UNKNOWN Continuation-in-part of Ser. No. US 1996-619304, filed on 21 Mar 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-603814, filed on 20 Feb 1996, GRANTED, Pat. No. US 5821072

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: COOPER & DUNHAM, 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 12 Drawing Page(s)

LINE COUNT: 5287

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor

cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 7 OF 10 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2001:140225 EPFULL  
DATA UPDATE DATE: 20040303  
DATA UPDATE WEEK: 200410  
TITLE (ENGLISH): Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or **radiotherapy**  
TITLE (FRENCH): L'acide lipoïque pour la suppression des effets indésirables hématologiques dans la chimiothérapie et/ou **radiothérapie**  
TITLE (GERMAN): Liponsäure zur Vermeidung unerwünschter haematologischer Wirkungen in der Chemotherapie und/oder **Radiotherapie**  
INVENTOR(S): Van Den Berg, Jeroen.J.M., Nassaulaan 21, NL-3971 HC Driebergen, NL; Osanto, Susanne., Prins Hendriklaan 10, NL-2341 JB Oegstgeest, NL; Hageman, Robert.J.J., Hamsterlaan 12, NL-6705 CT Wageningen, NL  
PATENT APPLICANT(S): N.V. Nutricia, (Nutricia, N.V.), Postbus 1, 2700 MA Zoetermeer, NL  
PATENT APPL. NUMBER: 923322  
AGENT: van Westenbrugge, Andries, et al, Nederlandsch Octrooibureau P.O. Box 29720, 2502 LS The Hague, NL 62593  
AGENT NUMBER:  
LANGUAGE OF FILING: English  
LANGUAGE OF PUBL.: English  
LANGUAGE OF PROCEDURE: English  
LANGUAGE OF TITLE: German; English; French  
DOCUMENT TYPE: Patent  
PATENT INFO TYPE: EPA1 Application published with search report  
PATENT INFORMATION:

	NUMBER	KIND	DATE
APPLICATION INFO.:	EP 1258243	A1	20021120
PRIORITY INFO.:	EP 2001-201835	A	20010516
	EP 2001-201835	A	20010516 *

ABEN

The present invention is concerned with a method of suppressing the detrimental effects of chemotherapy and/or **radiotherapy** on a patient's health. More specifically the invention relates to a method comprising the administration of a special pharmaceutical or dietetic preparation containing lipoic acid and/or lipoic acid analogue in an effective amount to suppress the reduction in blood cell count resulting from chemotherapy and/or **radiotherapy**. The invention also relates to a pharmaceutical or dietetic preparation comprising: lipoic acid and/or lipoic acid analogue in an amount which is equivalent to 40-2000 mg R(+) lipoic acid; 0.2-60 µmoles intact protein; 200-800 mg vitamin C; 100-500 mg vitamin D; 200-1000 mg N-acetyl cysteine and 5-100 mg zinc.

L1 ANSWER 8 OF 10 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 1999:60773 EPFULL  
DATA UPDATE DATE: 20040317  
DATA UPDATE WEEK: 200412  
TITLE (ENGLISH): PHARMACEUTICAL COMPOSITION IN PARTICULAR FOR PREVENTING AND TREATING **MUCOSITIS** INDUCED BY **RADIOThERAPY** OR CHEMOTHERAPY

TITLE (FRENCH) : COMPOSITION PHARMACEUTIQUE DESTINEE NOTAMMENT A LA  
 PREVENTION ET AU TRAITEMENT DES RADIOMUCITES ET DES  
 CHIMIOMUCITES  
 TITLE (GERMAN) : ARZNEIMITTEL INSBESONDERE ZUR VORBEUGUNG UND BEHANDLUNG  
 VON STRAHLUNGS- UND CHEMOMUKOSITIDEN  
 INVENTOR(S) : BESSE, Jerome, Galenix Developpement-Europarc, 14, rue  
 Gustave Hertz, 33600 Pessac, FR; NGUYEN, Tham,  
 Laboratoire L. Lafon, 19, avenue du Professeur Cadiot,  
 94701 Maisons Alfort, FR; LEYDER, Jo[ille, Laboratoire  
 L. Lafon, 19, avenue du Professeur Cadiot, 94701  
 Maisons Alfort, FR  
 PATENT APPLICANT(S) : LABORATOIRE L. LAFON, (L. LAFON, LABORATOIRE; LAFON,  
 LABORATOIRE L.), 19 Avenue du Professeur Cadiot, 94701  
 Maisons Alfort, FR  
 PATENT APPL. NUMBER: 212841  
 AGENT: Bernasconi, Jean Raymond, et al, c/o Cabinet Lavoix, 2,  
 Place d'Estienne d'Orves, 75441 Paris Cedex 09, FR  
 13927  
 AGENT NUMBER:  
 LANGUAGE OF FILING: French  
 LANGUAGE OF PUBL.: French  
 LANGUAGE OF PROCEDURE: French  
 LANGUAGE OF TITLE: German; English; French  
 DOCUMENT TYPE: Patent  
 PATENT INFO TYPE: EPB1 Granted patent .  
 PATENT INFORMATION:  
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	NUMBER	KIND	DATE
	EP 1098631	B1	20030326
	WO 2000004878		20000203
DESIGNATED STATES:	AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT SE		
APPLICATION INFO.:	EP 1999-929503	A	19990719
PRIORITY INFO.:	WO 1999-FR1760	A	19990719
CITED PATENT LIT.:	FR 1998-9230	A	19980720
	EP 380367	A	
	EP 386960	A	
	EP 577143	A	
	EP 648496	A	
	WO 9321905	A	
	US 5281196	A	
	US 5858371	A	

L1 ANSWER 9 OF 10 MEDLINE on STN  
 ACCESSION NUMBER: 92194148 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 1800734  
 TITLE: Management of oral **mucositis** during local  
 radiation and systemic chemotherapy: a study of 98  
 patients.  
 AUTHOR: Carl W; Emrich L S  
 CORPORATE SOURCE: Roswell Park Memorial Institute, School of Dental Medicine,  
 Buffalo, N.Y.  
 SOURCE: Journal of prosthetic dentistry, (1991 Sep) 66 (3) 361-9.  
 Journal code: 0376364. ISSN: 0022-3913.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Dental Journals; Priority Journals  
 ENTRY MONTH: 199204  
 ENTRY DATE: Entered STN: 19920509  
 Last Updated on STN: 19920509

Entered Medline: 19920420

AB Oral **mucositis** is among the complications of head and neck irradiation and systemic chemotherapy. To determine whether or not **mucositis** could be prevented or reduced in intensity by using Kamillasan Liquidum as an oral rinse, 98 patients were placed on study protocols. Twenty patients who were treated with radiation therapy and 46 patients who received systemic chemotherapy participated in prophylactic oral care with Kamillasan oral rinse. Thirty-two patients were treated therapeutically after **mucositis** had developed. Sixteen patients receiving chemotherapy were treated therapeutically and prophylactically with Kamillasan oral rinse during repeated cycles of chemotherapy. Only one of the 20 patients who had had radiation therapy developed grade 3 **mucositis** in the final week of treatment. Thirty-six of the 46 patients undergoing chemotherapy did not develop clinically noticeable **mucositis**. It appears that resolution of **mucositis** is accelerated by Kamillasan rinse. Prophylactic oral care appeared to modify the oral environment favorably and maintain tissue integrity.

L1 ANSWER 10 OF 10 EMBASE COPYRIGHT (c) 2005 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004506331 EMBASE

TITLE: Dietary antioxidants and human cancer.

AUTHOR: Borek C.

CORPORATE SOURCE: Dr. C. Borek, Dept. of Comm. Hlth. and Fam. Med., Nutrition Infectious Disease Unit, Tufts University School of Medicine, Boston, MA 02111, United States.

carmia.borek@tufts.edu

SOURCE: Integrative Cancer Therapies, (2004) Vol. 3, No. 4, pp. 333-341.

Refs: 64

ISSN: 1534-7354 CODEN: ICTNAY

COUNTRY: United States

DOCUMENT TYPE: Journal; Article

FILE SEGMENT: 014 Radiology

016 Cancer

017 Public Health, Social Medicine and Epidemiology

037 Drug Literature Index

038 Adverse Reactions Titles

LANGUAGE: English

SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20041217

Last Updated on STN: 20041217

AB Epidemiological studies show that a high intake of antioxidant-rich foods is inversely related to cancer risk. While animal and cell cultures confirm the anticancer effects of antioxidants, intervention trials to determine their ability to reduce cancer risk have been inconclusive, although selenium and vitamin E reduced the risk of some forms of cancer, including prostate and colon cancer, and carotenoids have been shown to help reduce breast cancer risk. Cancer treatment by radiation and anticancer drugs reduces inherent antioxidants and induces oxidative stress, which increases with disease progression. Vitamins E and C have been shown to ameliorate adverse side effects associated with free radical damage to normal cells in cancer therapy, such as **mucositis** and fibrosis, and to reduce the recurrence of breast cancer. While clinical studies on the effect of antioxidants in modulating cancer treatment are limited in number and size, experimental studies show that antioxidant vitamins and some phytochemicals selectively induce apoptosis in cancer cells but not in normal cells and prevent angiogenesis and metastatic spread, suggesting a potential role for antioxidants as adjuvants in cancer therapy.



## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptau153cxa

PASSWORD :

TERMINAL (ENTER 1, 2, 3, OR ?):2

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America  
NEWS 5 AUG 30 CA/CAPLus - Increased access to 19th century research documents  
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions  
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 8 SEP 22 MATHDI to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT  
MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP),  
AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS STN Operating Hours Plus Help Desk Availability  
NEWS INTER General Internet Information  
NEWS LOGIN Welcome Banner and News Items  
NEWS PHONE Direct Dial and Telecommunication Network Access to STN  
NEWS WWW CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 15:22:12 ON 27 SEP 2005

=> file caplus uspatful japiro epfull medline biosis embase scisearch  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST . . 0.84 0.84

FILE 'CAPLUS' ENTERED AT 15:24:34 ON 27 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 15:24:34 ON 27 SEP 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'JAPIO' ENTERED AT 15:24:34 ON 27 SEP 2005

COPYRIGHT (C) 2005 Japanese Patent Office (JPO) - JAPIO

FILE 'EPFULL' ENTERED AT 15:24:34 ON 27 SEP 2005

COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 15:24:34 ON 27 SEP 2005

FILE 'BIOSIS' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 15:24:34 ON 27 SEP 2005

Copyright (c) 2005 The Thomson Corporation

=> s mucositis and radiotherap? and (flavonoid# or isoflavonoid#)

L1 10 MUCOSITIS AND RADIOTHERAP? AND (FLAVONOID# OR ISOFLAVONOID#)

=> d 11 1-10 ibib abs

L1 ANSWER 1 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2003:855814 CAPLUS

DOCUMENT NUMBER: 139:333152

TITLE: Curcumin combination for the prevention and/or treatment of tissue damage

INVENTOR(S): Rezvani, Mohiaddin

PATENT ASSIGNEE(S): Isis Innovation Limited, UK

SOURCE: PCT Int. Appl., 34 pp.

CODEN: PIIXD2

DOCUMENT TYPE: Patent

LANGUAGE: English

FAMILY ACC. NUM. COUNT: 2

PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2003088986	A1	20031030	WO 2003-GB1694	20030416
W: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, YU, ZA, ZM, ZW				
RW: GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM, AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE, SI, SK, TR, BF, BJ, CF, CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD, TG				
GB 2387541	A1	20031022	GB 2002-8691	20020416
EP 1501526	A1	20050202	EP 2003-722760	20030416
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO, MK, CY, AL, TR, BG, CZ, EE, HU, SK				
PRIORITY APPLN. INFO.:			GB 2002-8691	A 20020416
			GB 2002-18412	A 20020808
			WO 2003-GB1694	W 20030416
AB	A combination of curcumin, an antioxidant, especially $\alpha$ -tocopherol, and at least one edible oil, especially sunflower oil, is useful in the prevention and/or treatment of tissue damage caused by non-phys. insult, especially <b>mucositis</b> or CNS damage caused by cancer therapy.			
REFERENCE COUNT:	5	THERE ARE 5 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT		

L1 ANSWER 2 OF 10 CAPLUS COPYRIGHT 2005 ACS on STN

ACCESSION NUMBER: 2000:84586 CAPLUS  
 DOCUMENT NUMBER: 132:127742  
 TITLE: Pharmaceutical composition in particular for preventing and treating **mucositis** induced by **radiotherapy** or chemotherapy comprising antiradical compounds  
 INVENTOR(S): Besse, Jerome; Nguyen, Tham; Leyder, Joelle  
 PATENT ASSIGNEE(S): Laboratoire L. Lafon, Fr.  
 SOURCE: PCT Int. Appl., 26 pp.  
 CODEN: PIXXD2  
 DOCUMENT TYPE: Patent  
 LANGUAGE: French  
 FAMILY ACC. NUM. COUNT: 1  
 PATENT INFORMATION:

PATENT NO.	KIND	DATE	APPLICATION NO.	DATE
WO 2000004878	A1	20000203	WO 1999-FR1760	19990719
W: AE, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZA, ZW, AM, AZ, BY, KG, KZ, MD, RU, TJ, TM				
RW: GH, GM, KE, LS, MW, SD, SL, SZ, UG, ZW, AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE, BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG				
FR 2781156	A1	20000121	FR 1998-9230	19980720
FR 2781156	B1	20010629		
CA 2337152	AA	20000203	CA 1999-2337152	19990719
AU 9946296	A1	20000214	AU 1999-46296	19990719
EP 1098631	A1	20010516	EP 1999-929503	19990719
EP 1098631	B1	20030326		
R: AT, BE, CH, DE, DK, ES, FR, GB, GR, IT, LI, LU, NL, SE, MC, PT, IE, SI, LT, LV, FI, RO				
JP 2002521321	T2	20020716	JP 2000-560871	19990719
AT 235226	E	20030415	AT 1999-929503	19990719
PT 1098631	T	20030630	PT 1999-929503	19990719
ES 2196823	T3	20031216	ES 1999-929503	19990719
PRIORITY APPLN. INFO.:			FR 1998-9230	A 19980720
			WO 1999-FR1760	W 19990719

AB The invention concerns a pharmaceutical composition designed to adhere to a mucous membrane in particular for preventing or treating **radiotherapy**-related and chemotherapy-related **mucositis**, induced by **radiotherapy** or combined radiochemotherapy, comprising an efficient amount of an antiradical compound mixed with a vehicle which is liquid at room temperature and gels at the mucous membrane temperature and capable of adhering to the mucous membrane by its gelled state. A pharmaceutical composition for buccal mucosa contained hydrosol. rutoside 2-10, Poloxamer-407 14.0, HPMC 1-3, fragrance 0.1-0.5, and buffer for pH = 7 q.s. 100%.

REFERENCE COUNT: 8 THERE ARE 8 CITED REFERENCES AVAILABLE FOR THIS RECORD. ALL CITATIONS AVAILABLE IN THE RE FORMAT

L1 ANSWER 3 OF 10 USPATFULL on STN  
 ACCESSION NUMBER: 2003:283125 USPATFULL  
 TITLE: Combination of bryostatin and paclitaxel for treating cancer  
 INVENTOR(S): Schwartz, Gary K., Briarcliff Manor, NY, UNITED STATES  
 Albino, Anthony P., New York, NY, UNITED STATES  
 PATENT ASSIGNEE(S): Sloan - Kettering Institute for Cancer Research (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003199469	A1	20031023
APPLICATION INFO.:	US 2002-215178	A1	20020807 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 1998-137442, filed on 20 Aug 1998, GRANTED, Pat. No. US 6444638 Continuation of Ser. No. WO 1997-US3341, filed on 20 Feb 1997, PENDING Continuation-in-part of Ser. No. US 1996-619304, filed on 21 Mar 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-603814, filed on 20 Feb 1996, GRANTED, Pat. No. US 5821072		
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	APPLICATION		
LEGAL REPRESENTATIVE:	John P. White, Cooper & Dunham LLP, 1185 Avenue of the Americas, New York, NY, 10036		
NUMBER OF CLAIMS:	35		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	12 Drawing Page(s)		
LINE COUNT:	5326		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 4 OF 10	USPATFULL	on STN
ACCESSION NUMBER:	2003:271068 USPATFULL	
TITLE:	Use of metabolic phenotyping in individualized treatment with amonafide	
INVENTOR(S):	Leyland-Jones, Brian, Miami, FL, UNITED STATES	
PATENT ASSIGNEE(S):	McGill University, Montreal, CANADA (U.S. corporation)	

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2003190671	A1	20031009
APPLICATION INFO.:	US 2002-124747	A1	20020416 (10)
RELATED APPLN. INFO.:	Continuation-in-part of Ser. No. US 2002-87996, filed on 28 Feb 2002, PENDING		

	NUMBER	DATE
PRIORITY INFORMATION:	US 2001-271714P	20010228 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133	
NUMBER OF CLAIMS:	88	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	31 Drawing Page(s)	
LINE COUNT:	8446	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug, amonafide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 5 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2003:200394 USPATFULL

TITLE: Use of metabolic phenotyping in individualized treatment with amonafide

INVENTOR(S): Leyland-Jones, Brian, Miami, FL, UNITED STATES

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION: US 2003138377 A1 20030724

APPLICATION INFO.: US 2002-87996 A1 20020228 (10)

	NUMBER	DATE
--	--------	------

PRIORITY INFORMATION: US 2001-271714P 20010228 (60)

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: HAMILTON, BROOK, SMITH & REYNOLDS, P.C., 530 VIRGINIA ROAD, P.O. BOX 9133, CONCORD, MA, 01742-9133

NUMBER OF CLAIMS: 88

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 29 Drawing Page(s)

LINE COUNT: 8181

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB The invention relates to the individualization of therapy on the basis of a phenotypic profile of an individual. More specifically, the present invention relates to the use of metabolic phenotyping for the individualization of treatment with the drug, amonafide.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 6 OF 10 USPATFULL on STN

ACCESSION NUMBER: 2001:123568 USPATFULL

TITLE: COMBINATIONS OF PKC INHIBITORS AND THERAPEUTIC AGENTS FOR TREATING CANCERS

INVENTOR(S): SCHWARTZ, GARY K., BRIARCLIFF MANOR, NY, United States ALBINO, ANTHONY P., NEW YORK, NY, United States

	NUMBER	KIND	DATE
--	--------	------	------

PATENT INFORMATION: US 2001011076 A1 20010802

US 6444638 B2 20020903

APPLICATION INFO.: US 1998-137442 A1 19980820 (9)

RELATED APPLN. INFO.: Continuation of Ser. No. WO 1997-US3341, filed on 20 Feb 1997, UNKNOWN Continuation-in-part of Ser. No. US 1996-619304, filed on 21 Mar 1996, ABANDONED Continuation-in-part of Ser. No. US 1996-603814, filed on 20 Feb 1996, GRANTED, Pat. No. US 5821072

DOCUMENT TYPE: Utility

FILE SEGMENT: APPLICATION

LEGAL REPRESENTATIVE: COOPER & DUNHAM, 1185 AVENUE OF THE AMERICAS, NEW YORK, NY, 10036

NUMBER OF CLAIMS: 35

EXEMPLARY CLAIM: 1

NUMBER OF DRAWINGS: 12 Drawing Page(s)

LINE COUNT: 5287

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides methods for screening a modulating agent which when combined with antitumor therapeutic agent increases apoptosis in tumor cells. This invention also provides methods for screening antitumor therapeutic agents suitable for combination therapy with a protein kinase C inhibitors capable of potentiating apoptosis in tumor

cells. This invention further provides different combination therapies comprising the specific protein kinase C inhibitors and the antitumor therapeutic agents.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L1 ANSWER 7 OF 10 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2001:140225 EPFULL  
DATA UPDATE DATE: 20040303  
DATA UPDATE WEEK: 200410  
TITLE (ENGLISH): Lipoic acid for suppressing undesired haematological effects of chemotherapy and/or **radiotherapy**  
TITLE (FRENCH): L'acide lipoïque pour la suppression des effets indésirables hématologiques dans la chimiothérapie et/ou **radiothérapie**  
TITLE (GERMAN): Liponsäure zur Vermeidung unerwünschter haematologischer Wirkungen in der Chemotherapie und/oder **Radiotherapie**  
INVENTOR(S): Van Den Berg, Jeroen.J.M., Nassaulaan 21, NL-3971 HC Driebergen, NL; Osanto, Susanne., Prins Hendriklaan 10, NL-2341 JB Oegstgeest, NL; Hageman, Robert.J.J., Hamsterlaan 12, NL-6705 CT Wageningen, NL  
PATENT APPLICANT(S): N.V. Nutricia, (Nutricia, N.V.), Postbus 1, 2700 MA Zoetermeer, NL  
PATENT APPL. NUMBER: 923322  
AGENT: van Westenbrugge, Andries, et al, Nederlandsch Octrooibureau P.O. Box 29720, 2502 LS The Hague, NL 62593  
AGENT NUMBER:  
LANGUAGE OF FILING: English  
LANGUAGE OF PUBL.: English  
LANGUAGE OF PROCEDURE: English  
LANGUAGE OF TITLE: German; English; French  
DOCUMENT TYPE: Patent  
PATENT INFO TYPE: EPAL Application published with search report  
PATENT INFORMATION:

	NUMBER	KIND	DATE
APPLICATION INFO.:	EP 1258243	A1	20021120
PRIORITY INFO.:	EP 2001-201835	A	20010516
	EP 2001-201835	A	20010516 *

ABEN

The present invention is concerned with a method of suppressing the detrimental effects of chemotherapy and/or **radiotherapy** on a patient's health. More specifically the invention relates to a method comprising the administration of a special pharmaceutical or dietetic preparation containing lipoic acid and/or lipoic acid analogue in an effective amount to suppress the reduction in blood cell count resulting from chemotherapy and/or **radiotherapy**. The invention also relates to a pharmaceutical or dietetic preparation comprising: lipoic acid and/or lipoic acid analogue in an amount which is equivalent to 40-2000 mg R(+) lipoic acid; 0.2-60 µmoles intact protein; 200-800 mg vitamin C; 100-500 mg vitamin D; 200-1000 mg N-acetyl cysteine and 5-100 mg zinc.

L1 ANSWER 8 OF 10 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 1999:60773 EPFULL  
DATA UPDATE DATE: 20040317  
DATA UPDATE WEEK: 200412  
TITLE (ENGLISH): PHARMACEUTICAL COMPOSITION IN PARTICULAR FOR PREVENTING AND TREATING **MUCOSITIS** INDUCED BY **RADIOThERAPY** OR CHEMOTHERAPY

TITLE (FRENCH): COMPOSITION PHARMACEUTIQUE DESTINEE NOTAMMENT A LA  
 PREVENTION ET AU TRAITEMENT DES RADIOMUCITES ET DES  
 CHIMIOMUCITES  
 TITLE (GERMAN): ARZNEIMITTEL INSSESONDERE ZUR VORBEUGUNG UND BEHANDLUNG  
 VON STRAHLUNGS- UND CHEMOMUKOSITIDEN  
 INVENTOR(S): BESSE, Jerome, Galenix Developpement-Europarc, 14, rue  
 Gustave Hertz, 33600 Pessac, FR; NGUYEN, Tham,  
 Laboratoire L. Lafon, 19, avenue du Professeur Cadiot,  
 94701 Maisons Alfort, FR; LEYDER, Jo[ille, Laboratoire  
 L. Lafon, 19, avenue du Professeur Cadiot, 94701  
 Maisons Alfort, FR  
 PATENT APPLICANT(S): LABORATOIRE L. LAFON, (L. LAFON, LABORATOIRE; LAFON,  
 LABORATOIRE L.), 19 Avenue du Professeur Cadiot, 94701  
 Maisons Alfort, FR  
 PATENT APPL. NUMBER: 212841  
 AGENT: Bernasconi, Jean Raymond, et al, c/o Cabinet Lavoix, 2,  
 Place d'Estienne d'Orves, 75441 Paris Cedex 09, FR  
 13927  
 AGENT NUMBER:  
 LANGUAGE OF FILING: French  
 LANGUAGE OF PUBL.: French  
 LANGUAGE OF PROCEDURE: French  
 LANGUAGE OF TITLE: German; English; French  
 DOCUMENT TYPE: Patent  
 PATENT INFO TYPE: EPB1 Granted patent  
 PATENT INFORMATION:  
 PATENT INFORMATION:

	NUMBER	KIND	DATE
	NUMBER	KIND	DATE
	EP 1098631	B1	20030326
	WO 2000004878		20000203

DESIGNATED STATES: AT BE CH CY DE DK ES FI FR GB GR IE IT LI LU MC NL PT  
 SE  
 APPLICATION INFO.: EP 1999-929503 A 19990719  
 WO 1999-FR1760 A 19990719  
 PRIORITY INFO.: FR 1998-9230 A 19980720  
 CITED PATENT LIT.: EP 380367 A  
 EP 386960 A  
 EP 577143 A  
 EP 648496 A  
 WO 9321905 A  
 US 5281196 A  
 US 5858371 A

L1 ANSWER 9 OF 10 MEDLINE on STN  
 ACCESSION NUMBER: 92194148 MEDLINE  
 DOCUMENT NUMBER: PubMed ID: 1800734  
 TITLE: Management of oral **mucositis** during local  
 radiation and systemic chemotherapy: a study of 98  
 patients.  
 AUTHOR: Carl W; Emrich L S  
 CORPORATE SOURCE: Roswell Park Memorial Institute, School of Dental Medicine,  
 Buffalo, N.Y.  
 SOURCE: Journal of prosthetic dentistry, (1991 Sep) 66 (3) 361-9.  
 Journal code: 0376364. ISSN: 0022-3913.  
 PUB. COUNTRY: United States  
 DOCUMENT TYPE: Journal; Article; (JOURNAL ARTICLE)  
 LANGUAGE: English  
 FILE SEGMENT: Dental Journals; Priority Journals  
 ENTRY MONTH: 199204  
 ENTRY DATE: Entered STN: 19920509  
 Last Updated on STN: 19920509

Entered Medline: 19920420

AB Oral **mucositis** is among the complications of head and neck irradiation and systemic chemotherapy. To determine whether or not **mucositis** could be prevented or reduced in intensity by using Kamillasan Liquidum as an oral rinse, 98 patients were placed on study protocols. Twenty patients who were treated with radiation therapy and 46 patients who received systemic chemotherapy participated in prophylactic oral care with Kamillasan oral rinse. Thirty-two patients were treated therapeutically after **mucositis** had developed. Sixteen patients receiving chemotherapy were treated therapeutically and prophylactically with Kamillasan oral rinse during repeated cycles of chemotherapy. Only one of the 20 patients who had had radiation therapy developed grade 3 **mucositis** in the final week of treatment. Thirty-six of the 46 patients undergoing chemotherapy did not develop clinically noticeable **mucositis**. It appears that resolution of **mucositis** is accelerated by Kamillasan rinse. Prophylactic oral care appeared to modify the oral environment favorably and maintain tissue integrity.

L1 ANSWER 10 OF 10 EMBASE COPYRIGHT (c) 2005 Elsevier B.V. All rights reserved on STN

ACCESSION NUMBER: 2004506331 EMBASE  
TITLE: Dietary antioxidants and human cancer.  
AUTHOR: Borek C.  
CORPORATE SOURCE: Dr. C. Borek, Dept. of Comm. Hlth. and Fam. Med., Nutrition Infectious Disease Unit, Tufts University School of Medicine, Boston, MA 02111, United States.  
carmia.borek@tufts.edu  
SOURCE: Integrative Cancer Therapies, (2004) Vol. 3, No. 4, pp. 333-341.

Refs: 64  
ISSN: 1534-7354 CODEN: ICTNAY

COUNTRY: United States  
DOCUMENT TYPE: Journal; Article  
FILE SEGMENT:  
014 Radiology  
016 Cancer  
017 Public Health, Social Medicine and Epidemiology  
037 Drug Literature Index  
038 Adverse Reactions Titles

LANGUAGE: English  
SUMMARY LANGUAGE: English

ENTRY DATE: Entered STN: 20041217  
Last Updated on STN: 20041217

AB Epidemiological studies show that a high intake of antioxidant-rich foods is inversely related to cancer risk. While animal and cell cultures confirm the anticancer effects of antioxidants, intervention trials to determine their ability to reduce cancer risk have been inconclusive, although selenium and vitamin E reduced the risk of some forms of cancer, including prostate and colon cancer, and carotenoids have been shown to help reduce breast cancer risk. Cancer treatment by radiation and anticancer drugs reduces inherent antioxidants and induces oxidative stress, which increases with disease progression. Vitamins E and C have been shown to ameliorate adverse side effects associated with free radical damage to normal cells in cancer therapy, such as **mucositis** and fibrosis, and to reduce the recurrence of breast cancer. While clinical studies on the effect of antioxidants in modulating cancer treatment are limited in number and size, experimental studies show that antioxidant vitamins and some phytochemicals selectively induce apoptosis in cancer cells but not in normal cells and prevent angiogenesis and metastatic spread, suggesting a potential role for antioxidants as adjuvants in cancer therapy.

=> FIL STNGUIDE

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	44.71	45.55
DISCOUNT AMOUNTS (FOR QUALIFYING ACCOUNTS)	SINCE FILE ENTRY	TOTAL SESSION
CA SUBSCRIBER PRICE	-1.46	-1.46

FILE 'STNGUIDE' ENTERED AT 15:33:08 ON 27 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR CUSTOMER AGREEMENT  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY, JAPAN SCIENCE  
AND TECHNOLOGY CORPORATION, AND FACHINFORMATIONSZENTRUM KARLSRUHE

FILE CONTAINS CURRENT INFORMATION.  
LAST RELOADED: Sep 23, 2005 (20050923/UP).



similar results 45. example of longevity related medline abstracts -(long!) [42K]

Oct 2004

...by using the single-cell **gel** electrophoresis assay (comet...protective than the conjugated **flavonoids** (eg, quercetin compared with...antioxidant activity of free **flavonoids** is related to the number...47, 1997. Abstract Thirteen **isoflavonoids**, **flavonoids**, and lignans, including some...

[<http://www.cryonet.org/cgi-bin/dsp.cgi?msg=11859>]

similar results 46. Brazilian Journal of Medical and Biological Research - Antioxidant properties of natural compounds used in popular medicine ... [59K]**M.G. Repetto / S.F. Llesuy**, Jan 2005

...phenolic antioxidants such as **flavonoids**, tannins, coumarins, xanthenes...adherent and transparent **gel** formed by 95% water and 5...barrier depend not only on the **gel** structure but also on the...triterpene glycoside glycyrrhizin, **flavonoids** (liquiritin and isoliquiritin), **isoflavonoids** (isoflavanol, kumatakenin...)

more hits from [[http://www.scielo.br/scielo.php?script=sci\\_arttext&pid...](http://www.scielo.br/scielo.php?script=sci_arttext&pid...)]

similar results 47. Corsifurans A-C, 2-arylbenzofurans of presumed stilbenoid origin from Corsinia coriandrina (Hepaticae)**von Reusz, S.H. / Konig, W.A.**, *Phytochemistry*, Dec 2004

...In comparison to **flavonoids** (2), **isoflavonoids** (3) and stilbenoids...chromatographed on silica **gel** 60 F 254 (Merck) using...plates with silica **gel** 60 F 254 (Merck) using...Antimicrobial and antioxidant **flavonoids** from the root wood...

**Full text article available from** 

similar results 48. COSMETIC COMPOSITION FOR PREVENTING AND/OR CORRECTING THE FUNCTIONAL DISORDERS OF THE PILO-SEBACEOUS UNIT OF MAMMALS**DURANTON, Albert / MALNOE, Armand / L'OREAL, PATENT COOPERATION TREATY APPLICATION**, Apr 2004

...from the vine and tea. 25 The **isoflavonoids** constitute a sub-class of the **flavonoids**. They are I formed of a 3-phenylchromane...of oxidation. Contrary to the **flavonoids**, the **isoflavonoids** are present in only a very limited...Isoflavonoids" of the 5 monograph "The **Flavonoids**" (Dewick, P.M. Harbone Ed. pp. 125-157 (1 988)). **Isoflavonoids** particularly suited to being implemented...

**Full text available at patent office. For more in-depth searching go to** 

similar results 49. United States Patent: 5,733,759 [75K]

Jul 2002

...Tunen, "F1 hybrid seed production and **flavonoids**," Prophyta, Jun. 1992, pp. 56-58. Primary...in post-dispersal pollen function. **Flavonoids** are an abundant class of small molecular...violet plant colors. Other pigmented **flavonoids**, the chalcones, and some flavonols and...

[<http://wsurf5.respark.wsu.edu/US%20Issued%20Patents%20...>]

similar results 50. Expression of a putative flavonoid 3'-hydroxylase in sorghum mesocotyls synthesizing 3-deoxyanthocyanidin phytoalexins

**Boddu, J. / Svabek, C. / Sekhon, R. / Gevens, A. / Nicholson, R.L. / Jones, A.D. / Pedersen, J.F. / (...) / Chopra, S.**, *Physiological and Molecular Plant Pathology*, Aug 2004

...ofchs,f3'h, anddfrgenes in sorghum. RNA **gel** blots were prepared from total RNA...importance as a molecular genetic system, **flavonoids** are involved in various biological...as explained below. 2.2 DNA and RNA **gel** blot hybridizations Plant genomic DNA...

**Full text article available from**   
[similar results](#)

- 51.** [Plant cell factories in the post-genomic era: new ways to produce designer secondary metabolites](#)

**Oksman-Caldentey, K.-M. / Inze, D.**, *Trends in Plant Science*, Sep 2004  
...terpenoids), alkaloids, phenylpropanoids and **flavonoids**. The polyketides are produced via the...acids phenylalanine or tyrosine and the **flavonoids** are synthesized by the combination of...certain plant families. By contrast, **flavonoids** are abundant in many plant species...

**Full text article available from**   
[similar results](#)

- 52.** [No Job Name \[PDF-25K\]](#)

Apr 2005

...potencies among these and other common **flavonoids**. The flavones kaempferol and dihydroquer...by column chromatography using silica **gel** with hexane/ethyl acetate (80:20) to...phytotoxicity of catechins and other **flavonoids**: flavonoid conversions by cell-free protein...

[more hits from](#) [<http://crb.colostate.edu/home/Assets/papers/Ravi2004.pdf>...]  
[similar results](#)

- 53.** [Antibacterial property of isoflavonoids isolated from Erythrina variegata against cariogenic oral bacteria](#)

**Sato, M. / Tanaka, H. / Fujiwara, S. / Hirata, M. / Yamaguchi, R. / Etoh, H. / Tokuda, C.**, *Phytomedicine*, Jan 2003

...Leguminosae) by repeated silica **gel** column chromatography, against...words Cariogenic bacteria **isoflavonoids** antibacterial activity Erythrina...Havsteen, 1983 B. Havsteen **Flavonoids**, a class of natural products...Z. Khan M. Anwar Three new **isoflavonoids** from Erythrina variegata Heterocycles...

**Full text article available from**   
[similar results](#)

- 54.** [Measuring educational gains and setting consequences charter schooling and the no child left behind policy /](#)

**Lyttle, Erin.**, Jan 2004

Thesis (M.A.)--Duquesne University, 2004. Title from document title page. Abstract included in electronic submission form. Includes bibliographical references (p. 81-85) and abstract.

**Full text thesis available via NDLTD**

[similar results](#)

- 55.** [Learning to create : a collection of personal essays /](#)

**1973- Christiansen, Naomi Lund**,, Jan 2004

Thesis (M.A.)--Brigham Young University. Dept. of English, 2004. Includes bibliographical references.

**Full text thesis available via NDLTD**

[similar results](#)

- 56.** [Biotransformation of soy isoflavone-glycosides in laying hens: intestinal absorption and preferential accumulation into...](#)

**Saitoh, S. / Sato, T. / Harada, H. / Matsuda, T.**, *Biochimica et Biophysica Acta (BBA)/General Subjects*, Sep 2004

...All of the serum and yolk fractions were subjected to protein composition analysis by sodium dodecyl sulfate-polyacrylamide **gel** electrophoresis (SDS-PAGE) according to Laemmli's method [27] and isoflavone quantitative analysis. 2.8 Statistics Data are presented...

**Full text article available from** 

[similar results](#)

57. [Bioreduction of hexavalent chromium flow-through column experiments and reactive transport modeling / 1970- Alam, Md Mahbub,, Jan 2004](#)  
Thesis (Ph. D. in Civil Engineering)--Washington State University. Includes bibliographical references.  
**Full text thesis available via NDLTD**  
[similar results](#)
58. [Kaempferol blocks oxidative stress in cerebellar granule cells and reveals a key role for reactive oxygen species...](#)  
**Samhan-Arias, A.K. / Martin-Romero, F.J. / Gutierrez-Merino, C., Free Radical Biology and Medicine, Jul 2004**  
...this redox chain [24,27] . **Flavonoids** constitute a group of polyphenolic...ubiquinone (0.06-0.1 V) [31] . As **flavonoids** are also lipophilic compounds...tested the hypothesis that some **flavonoids** could be interfering with...electrophoresis in a 1.2% agarose-TBE gel. NADH oxidase activity NADH...  
**Full text article available from**   
[similar results](#)
59. [Virginia Bioinformatics Institute - Project Summary \[8K\]](#)  
May 2005  
...SRNF). It is a rich source of natural products, such as **flavonoids**, **isoflavonoids** and triterpenes, which impact its properties as a forage...program) ii) protein expression patterns using two-dimensional **gel** electrophoresis and mass spectrometry (MALDI-TOF and Q-TOF...  
[more hits from](http://research.vbi.vt.edu/article/articleprint/133/-1...) [\[http://research.vbi.vt.edu/article/articleprint/133/-1...\]](http://research.vbi.vt.edu/article/articleprint/133/-1...)  
[similar results](#)
60. [Agrobacterium-mediated transformation in the high-value medicinal plant Echinacea purpurea](#)  
**Wang, H.-M. / To, K.-Y., Plant Science, Apr 2004**  
...classes (flavonols, flavones, **isoflavonoids**, and anthocyanins) of **flavonoids**. **Flavonoids** are a large class of plant...fruits, seeds, and leaves, **flavonoids** also play key roles in...product was run on 1% agarose **gel** ). The expression vector...  
**Full text article available from**   
[similar results](#)



**Results Pages:** [[<< Prev](#)] [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [[Next >>](#)] [back to top](#)

[Downloads](#) | [Subscribe to News Updates](#) | [User Feedback](#) | [Advertising](#)  
[Test Zone](#) | [Tell A Friend](#) | [Terms Of Service](#) | [Privacy Policy](#) | [Legal](#)

[Powered by FAST](#) © Elsevier 2005



## Questions about DVT?



About Us

Newsfrom

#### **Advisory Board**

[Submit Web Site](#)

Search Tips

Contact us

## Basic Search

Advanced Search Search Preferences

Search

图 1-1-100 例 8-6-1(MATLAB)

Journal sources    Preferred Web sources    Other Web sources    Exact phrases

Searched for:: :All of the words:(**flavonoids** or **isoflavonoids**) and **gel**


Found:: **8,758 total | 4,245 journal results | 1,411 preferred web results | 3,102 other web re**

Sort by:: [relevance](#) | [date](#)

### Save checked results:

### Email checked results

### Export checked results

- 1. Flavonoids and isoflavonoids from Genista morisii  
**Giachi, I. / Manunta, A. / Morelli, I. / Pistelli, L., Biochemical Systematics and Ecology**, Aug 2002  
...01)00116-8 **Flavonoids and isoflavonoids** from Genista morisii Isa...Genista morisii Leguminosae **Flavonoids Isoflavonoids** Chemotaxonomy 1 Subject...Genista is known to contain **flavonoids** as well as lupine-type quinolizidine...C 11 were applied to Si gel column chromatography eluted...  
**Full text article available from**   
[similar results](#)
  - 2. Two prenylated flavonoids from the stem bark of Erythrina burttii  
**Yenesew, A. / Irungu, B. / Derese, S. / Midiwo, J.O. / Heydenreich, M. / Peter, M.G., Phytochemistry**, Jun 2003  
...**flavonoids and isoflavonoids**. Some of the flavanones...have reported new **flavonoids and isoflavonoids** from the stem...plant three known **isoflavonoids** were also isolated...coated silica gel 60 F 254 plates. CC on silica gel 60 (70-230 mesh...  
**Full text article available from**   
[similar results](#)
  - 3. Effects of the Flavonoids Biochanin A, Morin, Phloretin, and Silymarin on P-Glycoprotein-Mediated Transport -- Zhang and Morris ... [136K]  
**Zhang, S / Shuzhong Zhang / Marilyn E. Morris , Oct 2004**  
...March 2003 Effects of the **Flavonoids** Biochanin A, Morin, Phloretin...Results Discussion References **Flavonoids** are constituents of fruits...was incubated with 100 µM **flavonoids**, or solvent control (0.2...a 7.5% SDS-polyacrylamide **gel** electrophoresis. Gels were...  
[\[http://jpet.aspetjournals.org/cgi/content/full/304/3/1...\]](http://jpet.aspetjournals.org/cgi/content/full/304/3/1...)  
[similar results](#)
  - 4. Mass spectrometric methods for the determination of flavonoids in biological samples  
**Prasain, J.K. / Wang, C.-C. / Barnes, S., Free Radical Biology and Medicine**, Nov 2004  
...There are certain hydroxyl groups in **flavonoids** that are usually glycosylated. These...with the adjacent carbonyl at C-4. **Isoflavonoids** are **flavonoids** with ring B attached to the C-3...of the heterocyclic ring of the **isoflavonoids** can occur [27]. **Flavonoids** are converted to several other phenolic...

**Full text article available from**  [similar results](#)

5. Isoflavonoids from Dalbergia olivari

**Ito, C. / Itoigawa, M. / Kanematsu, T. / Ruangrungsi, N. / Mukainaka, T. / Tokuda, H. / Nishino, H. / Furukawa, H.**, *Phytochemistry*, Dec 2003  
...Japan, Gifu, March, 2000. **Isoflavonoids** from *Dalbergia olivari* Chihiro...subjected successively to silica **gel** column chromatography and...Dewick, 1988 Dewick P.M.  
**Isoflavonoids** Harborne J.B. The **Flavonoids**, Chapter 5 1988 125 209...1976 Ingham J.L. Induced **isoflavanoids** from fungus-infected stems...

**Full text article available from**  [similar results](#)

6. Biological activity of five antibacterial flavonoids from Combretum erythrophyllum (Combretaceae)

**Martini, N.D. / Katerere, D.R.P. / Eloff, J.N.**, *Journal of Ethnopharmacology*, Aug 2004  
...activity of five antibacterial **flavonoids** from *Combretum erythrophyllum*...and closed column Silica **gel** chromatography and collected...chickpea ( Ibrahim, 2000 ).  
**Flavonoids** have been reported to be...selectively inhibited by **flavonoids** and **isoflavanoids** derived from plants. Basile...

**Full text article available from**  [similar results](#)

7. NITRIC OXIDE DONATING DERIVATIVES FOR THE TREATMENT OF CARDIOVASCULAR DISORDERS

**WONG, Norman / TUCKER, Joe / MCCAFFREY, David, Robert / RESVERLOGIX CORP., PATENT COOPERATION TREATY APPLICATION**, Apr 2005  
...field of synthesis and administration of **flavonoids** and derivatives thereof suitable for...molecule. STILBENES, POLYPHENOLS AND **FLAVONOIDS** AS ANTI-OXIDANTS Reactive oxygen species...the ROS. Stilbenes, polyphenols and **flavonoids** all contain at least two phenolic ring...

**Full text available at patent office. For more in-depth searching go to**  LexisNexis  
[similar results](#)

8. Prenylated flavonoids from Deguelia hatschbachii and their systematic significance in Deguelia

**Magalhaes, A.F. / Tozzi, A.M.G.A. / Magalhaes, E.G. / Moraes, V.R.S.**, *Phytochemistry*, May 2001  
...compounds furnished by *Deguelia* species **Flavonoids Isoflavonoids** Stilbene Chalcone Flavanone Isoflavanone...Contents (mg/g of roots) Extract **Flavonoids** Petrol Dichloromethane 1 nd b 12...b nd=not detected.). Thus the **flavonoids** of *D. hatschbachii* mainly consist of **isoflavanoids**, as observed for the *Deguelia* species...

**Full text article available from**  [similar results](#)

9. Flavonoids from the stem bark of Bolusanthus speciosus

**Bojase, G. / Wanjala, C.C.W. / Majinda, R.R.T.**, *Phytochemistry*, Apr 2001  
...speciosus revealed the presence of **isoflavanoids** ( Ascres et al., 1985 ). From methanolic...stem bark of *B. speciosus* , three new **isoflavanoids** were isolated and characterization of...vacuum liquid chromatography- silica **gel** HF 254 5-15 mu m mesh (Merck) Sephadex...

**Full text article available from**  [similar results](#)

10. Effects of dietary flavonoids on major signal transduction pathways in human epithelial cells

**O'Prey, J. / Brown, J. / Fleming, J. / Harrison, P.R.**, *Biochemical Pharmacology*, Dec

2003

...00593-8 Elsevier Inc. Effects of dietary **flavonoids** on major signal transduction pathways...Bearsden, Glasgow G61 1BD, Scotland, UK **Flavonoids** (FVs) are an important class of plant...levels, various naturally-occurring **flavonoids** have been shown to be cancer-protective...

**Full text article available from**  [similar results](#)

**11. Prenylated flavonoids from *Moghania philippinensis***

**Ahn, E.-M. / Nakamura, N. / Akao, T. / Komatsu, K. / Qui, M.-H. / Hattori, M.,**  
*Phytochemistry*, Dec 2003

...of China Five prenylated **flavonoids**, 8-(1,1-dimethylallyl)genistein...chemical means. Five prenylated **flavonoids** were isolated from the roots...regard chemical constituents, **isoflavonoids**, prenylated **flavonoids**, flemiphilippines A, B...Sephadex LH-20 and silica **gel** to give five new compounds...

**Full text article available from**  [similar results](#)

**12. CHERRY EXTRACTS FOR INHIBITING CYCLOOXYGENASE ENZYMES**

**NAIR, Muraleedharan, G. / WANG, Haibo / STRASBURG, Gale, M. / BOOREN, Alden, M. / GRAY, James, I. / MICHIGAN STATE UNIVERSITY, EUROPEAN PATENT,**  
Oct 2001

...effect of PGHS-1 (COX-1) by **flavonoids** and **isoflavonoids** at 200 µm concentrations...PGHS- 1 enzyme (COX-1) by **flavonoids** from BALATON tart cherries...PGHS-1 enzyme (COX-1) by **isoflavonoids** from BALATON tart cherries...further purified by silica **gel** vacuum liquid chromatography...

**Full text available at patent office. For more in-depth searching go to**  [LexisNexis](#)  
[similar results](#)

**13. Sulfation of Flavonoids and Other Phenolic Dietary Compounds by the Human Cytosolic Sulfotransferases**

**Pai, T.G. / Suiko, M. / Sakakibara, Y. / Liu, M.-C., Biochemical and Biophysical Research Communications**, Aug 2001

...sulfate-polyacrylamide **gel** electrophoresis. Sulfation...has focused attention on **flavonoids**, **isoflavonoids**, and other phenolic dietary...sulfation of representative **flavonoids**, **isoflavonoids**, anti-oxidants, and other...high activity with the **flavonoids** but not with the **isoflavonoids**. SULT1C ST #2 showed high...

**Full text article available from**  [similar results](#)

**14. Characterization of O-methyltransferase ScOMT1 cloned from *Streptomyces coelicolor* A3 (2)**

**Yoon, Y. / Yi, Y.S. / Lee, Y. / Kim, S. / Kim, B.G. / Ahn, J.H. / Lim, Y., BBA - Gene Structure and Expression**, Aug 2005

...affinity chromatography. SDS-PAGE **gel** was stained with Coomassie...vivo and in vitro analysis of **flavonoids** and related compounds using...nutrients to the residents[1]. **Flavonoids** are one of the compounds found...bacteria[1,2]. In addition, since **flavonoids** contain 15-carbon which forms...

**Full text article available from**  [similar results](#)

**15. Differential interaction of *Sophora* isoflavonoids with lipid bilayers**

**Hendrich, A.B. / Malon, R. / Pola, A. / Shirataki, Y. / Motohashi, N. / Michalak, K., European Journal of Pharmaceutical Sciences**, Aug 2002

...compounds are **flavonoids** or **isoflavonoids** differing mainly in...the interactions of **flavonoids** or **isoflavonoids** with lipid membranes...The values of the **gel**-liquid crystalline...decreasing of the lipid **gel**-liquid crystalline...results obtained for **flavonoids** other than those studied...

**Full text article available from**  [similar results](#)

16. 7a-O-methyldequelol, a modified rotenoid with an open ring-C, from the roots of *Derris trifoliata*

**Yenesew, A. / Mushibe, E.K. / Induli, M. / Derese, S. / Midiwo, J.O. / Kabaru, J.M. / Heydenreich, M. / (...) / Peter, M.G.,** *Phytochemistry*, Mar 2005  
...et al., 1989 E. Dagne A. Yenesew P.G. Waterman **Flavonoids** and **isoflavonoids** from Tephrosia fulvinervis and Tephrosia pentaphylla...1994 P.M. Dewick **Isoflavonoids** J.B. Harborne **Flavonoids:** advances in research since 1986 1994 Chapman...

**Full text article available from**  [similar results](#)

17. Comparative phytochemical analysis of four Mexican *Nymphaea* species

**Marquina, S. / Bonilla-Barbosa, J. / Alvarez, L.**, *Phytochemistry*, Apr 2005  
...1999 ), as well as two rare macrocyclic **flavonoids** from N. lotus ( Elegami et al., 2003...EtOAc (85:15), was applied to a silica **gel** CC (400 g) eluted with a gradient mixture...hexane-EtOAc (1:1) was subjected to silica **gel** CC, eluted with CH<sub>2</sub>Cl<sub>2</sub> - MeOH (gradient...

**Full text article available from**  [similar results](#)

18. Identification of a novel zebrafish SULT1 cytosolic sulfotransferase: cloning, expression, characterization, and...

**Ming-Yih Liu / Yuh-Shyong Yang / Takuya Sugahara / Shin Yasuda / Ming-Cheh Liu, Arch Biochem Biophys**, May 2005  
...35kDa protein upon sodium dodecyl sulfate-polyacrylamide **gel** electrophoresis. Among the endogenous compounds tested as...activities toward a number of xenobiotics including some **flavonoids**, **isoflavonoids**, and other phenolic compounds, with a pH optimum at 7.0...

**MEDLINE/PubMed Citation on** 

[similar results](#)

19. Flavonoids and isoflavonoids from Tephrosia fulvinervis and Tephrosia pentaphylla

**Dagne, E. / Yenesew, A. / Waterman, P.G.,** *Phytochemistry*, Jan 1989  
...for elaborating **flavonoids** and **isoflavonoids** [1]. As part of...to be rich in **flavonoids**. It proved possible...extracted with petrol **Flavonoids** of Tephrosia 3209...graphy over silica **gel** eluting with petrol...PTLC on silica **gel** (solvent: C<sub>6</sub>H<sub>6</sub>...

**Full text article available from**  [similar results](#)

20. Contexts for Facilitating Emergent Literacy in Typically Developing Preschoolers

**Wilhjelm, Karen Nicole**, Apr 2004

The purpose of this study was to investigate if there is an additive benefit in training Emergent Literacy (EL) skills with typically developing preschoolers using a combined intervention approach, Dialogic Reading (DR) plus classroom Phonological ...

**Full text thesis available via NDLTD**

[similar results](#)

last >

**Results Pages:** [[<< Prev](#)] [1](#) [2](#) [3](#) [4](#) [5](#) [6](#) [7](#) [8](#) [9](#) [10](#) [11](#) [12](#) [13](#) [14](#) [15](#) [16](#) [17](#) [18](#) [19](#) [20](#) [[Next >>](#)] [back to top](#)

## Connecting via Winsock to STN

Welcome to STN International! Enter x:x

LOGINID: sssptau153cxa

## PASSWORD:

TERMINAL (ENTER 1, 2, 3, OR ?) :2

\* \* \* \* \* \* \* \* \* \* \* \* \* \* \* \* Welcome to STN International \* \* \* \* \* \* \* \* \* \* \* \* \* \* \*

NEWS 1 Web Page URLs for STN Seminar Schedule - N. America  
NEWS 2 "Ask CAS" for self-help around the clock  
NEWS 3 JUL 20 Powerful new interactive analysis and visualization software,  
STN AnaVist, now available  
NEWS 4 AUG 11 STN AnaVist workshops to be held in North America  
NEWS 5 AUG 30 CA/CAplus - Increased access to 19th century research documents  
NEWS 6 AUG 30 CASREACT - Enhanced with displayable reaction conditions  
NEWS 7 SEP 09 ACD predicted properties enhanced in REGISTRY/ZREGISTRY  
NEWS 8 SEP 22 MATHDI to be removed from STN

NEWS EXPRESS JUNE 13 CURRENT WINDOWS VERSION IS V8.0, CURRENT MACINTOSH VERSION IS V6.0c(ENG) AND V6.0Jc(JP), AND CURRENT DISCOVER FILE IS DATED 13 JUNE 2005

NEWS HOURS	STN Operating Hours Plus Help Desk Availability
NEWS INTER	General Internet Information
NEWS LOGIN	Welcome Banner and News Items
NEWS PHONE	Direct Dial and Telecommunication Network Access to STN
NEWS WWW	CAS World Wide Web Site (general information)

Enter NEWS followed by the item number or name to see news on that specific topic.

All use of STN is subject to the provisions of the STN Customer agreement. Please note that this agreement limits use to scientific research. Use for software development or design or implementation of commercial gateways or other similar uses is prohibited and may result in loss of user privileges and other penalties.

FILE 'HOME' ENTERED AT 16:14:51 ON 27 SEP 2005

=> file caplus uspatful epfull medline japiro biosis embase scisearch  
COST IN U.S. DOLLARS SINCE FILE TOTAL  
ENTRY SESSION  
FULL ESTIMATED COST 0.21 0.21

FILE 'CAPLUS' ENTERED AT 16:15:19 ON 27 SEP 2005  
USE IS SUBJECT TO THE TERMS OF YOUR STN CUSTOMER AGREEMENT.  
PLEASE SEE "HELP USAGETERMS" FOR DETAILS.  
COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'USPATFULL' ENTERED AT 16:15:19 ON 27 SEP 2005  
CA INDEXING COPYRIGHT (C) 2005 AMERICAN CHEMICAL SOCIETY (ACS)

FILE 'EPEU11J' ENTERED AT 16:15:19 ON 27 SEP 2005

COPYRIGHT (C) 2005 European Patent Office / FIZ Karlsruhe

FILE 'MEDLINE' ENTERED AT 16:15:19 ON 27 SEP 2005

FILE 'JAPIO' ENTERED AT 16:15:19 ON 27 SEP 2005

COPYRIGHT (C) 2005 Japanese Patent Office (JPO) - JAPIO

FILE 'BIOSIS' ENTERED AT 16:15:19 ON 27 SEP 2005

Copyright (c) 2005 The Thomson Corporation

FILE 'EMBASE' ENTERED AT 16:15:19 ON 27 SEP 2005

Copyright (c) 2005 Elsevier B.V. All rights reserved.

FILE 'SCISEARCH' ENTERED AT 16:15:19 ON 27 SEP 2005

Copyright (c) 2005 The Thomson Corporation

=> Gel? and (isoflavanoid? or flavonoid?)

GEL? IS NOT A RECOGNIZED COMMAND

The previous command name entered was not recognized by the system.

For a list of commands available to you in the current file, enter  
"HELP COMMANDS" at an arrow prompt (>).

=> s Gel? and (isoflavanoid? or flavonoid?)

L1 6275 GEL? AND (ISOFLAVONOID? OR FLAVONOID?)

=> s l1 and sol(w)gel

L2 42 L1 AND SOL(W) GEL

=> s l2 and (poloxamer? or poloxamine? or divinylbenzenesorbitol)

L3 5 L2 AND (POLOXAMER? OR POLOXAMINE? OR DIVINYLBENZENESORBITOL)

=> s l3 and (rutoside or diosmin or quercitin or tangeretin or hesperidin or genistein or daidzin or glycitin or rutin)

L4 0 L3 AND (RUTOSIDE OR DIOSMIN OR QUERCITIN OR TANGERETIN OR HESPERIDIN OR GENISTEIN OR DAIDZIN OR GLYCITIN OR RUTIN)

=> d l3 1-5 ibib abs

L3 ANSWER 1 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2004:95506 USPATFULL

TITLE: Multiblock biodegradable hydrogels for drug delivery and tissue treatment

INVENTOR(S): Pathak, Chandrashekhar P., Austin, TX, UNITED STATES  
Barman, Shikha P., Bedford, MA, UNITED STATES  
Philbrook, C. Michael, Boston, MA, UNITED STATES  
Sawhney, Amarpreet S., Lexington, MA, UNITED STATES  
Couri, Arthur J., Boston, MA, UNITED STATES  
Avila, Luis Z., Arlington, MA, UNITED STATES  
Kieras, Mark T., Burlingame, CA, UNITED STATES

PATENT ASSIGNEE(S): Focal, Inc (U.S. corporation)

NUMBER	KIND	DATE
--------	------	------

PATENT INFORMATION: US 2004072961 A1 20040415

US 6923986 B2 20050802

APPLICATION INFO.: US 2003-650163 A1 20030827 (10)

RELATED APPLN. INFO.: Division of Ser. No. US 2002-114722, filed on 2 Apr 2002, GRANTED, Pat. No. US 6639014 Continuation of Ser. No. US 2000-710416, filed on 9 Nov 2000, GRANTED, Pat. No. US 6410645 Division of Ser. No. US 1996-692914, filed on 26 Jul 1996, GRANTED, Pat. No. US 6201065

NUMBER	DATE
--------	------

PRIORITY INFORMATION: US 1995-1723P 19950728 (60)  
DOCUMENT TYPE: Utility  
FILE SEGMENT: APPLICATION  
LEGAL REPRESENTATIVE: GENZYME CORPORATION C/O HOLLAND & KNIGHT, LLP, HOLLAND & KNIGHT, LLP, ONE ATLANTIC CENTER, 1201 WEST PEACHTREE STREET, N.E., ATLANTA, GA, 30309-3400

NUMBER OF CLAIMS: 50  
EXEMPLARY CLAIM: 1  
NUMBER OF DRAWINGS: 8 Drawing Page(s)  
LINE COUNT: 1475

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 2 OF 5 USPATFULL on STN  
ACCESSION NUMBER: 2002:273521 USPATFULL  
TITLE: Multiblock biodegradable hydrogels for drug delivery and tissue treatment  
INVENTOR(S): Pathak, Chandrashekhar P., Austin, TX, UNITED STATES  
Barman, Shikha P., Bedford, MA, UNITED STATES  
Philbrook, C. Michael, Boston, MA, UNITED STATES  
Sawhney, Amarpreet S., Lexington, MA, UNITED STATES  
Couri, Arthur J., Boston, MA, UNITED STATES  
Avila, Luis Z.; Arlington, MA, UNITED STATES  
Kieras, Mark T., Menlo Park, CA, UNITED STATES  
PATENT ASSIGNEE(S): Focal, Inc. (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2002151650	A1	20021017
	US 6639014	B2	20031028
APPLICATION INFO.:	US 2002-114722	A1	20020402 (10)
RELATED APPLN. INFO.:	Continuation of Ser. No. US 2000-710416, filed on 9 Nov 2000, GRANTED, Pat. No. US 6410645 Division of Ser. No. US 1996-692914, filed on 26 Jul 1996, GRANTED, Pat. No. US 6201065		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-1723P	19950728 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	PATREA L. PABST, HOLLAND & KNIGHT LLP, SUITE 2000, ONE ATLANTIC CENTER, 1201 WEST PEACHTREE STREET, N.E., ATLANTA, GA, 30309-3400	
NUMBER OF CLAIMS:	50	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	8 Drawing Page(s)	
LINE COUNT:	1480	
CAS INDEXING IS AVAILABLE FOR THIS PATENT.		
AB	Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a	

tissue surface *in vivo*. The **gels** formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 3 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2002:152720 USPATFULL

TITLE: Multiblock biodegradable hydrogels for drug delivery and tissue treatment

INVENTOR(S): Pathak, Chandrashekhar P., Lexington, MA, United States  
Barman, Shikha P., Bedford, MA, United States  
Philbrook, C. Michael, Boston, MA, United States  
Sawhney, Amarpreet S., Lexington, MA, United States  
Couri, Arthur J., Boston, MA, United States  
Avila, Luis Z., Arlington, MA, United States  
Kieras, Mark T., Burlingame, CA, United States  
Focal, Inc., Lexington, MA, United States (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6410645	B1	20020625
APPLICATION INFO.:	US 2000-710416		20001109 (9)
RELATED APPLN. INFO.:	Division of Ser. No. US 1996-692914, filed on 26 Jul 1996, now patented, Pat. No. US 6201065		

	NUMBER	DATE
PRIORITY INFORMATION:	US 1995-1723P	19950728 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	GRANTED	
PRIMARY EXAMINER:	Yoon, Tae H.	
LEGAL REPRESENTATIVE:	Holland & Knight LLP	
NUMBER OF CLAIMS:	9	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	20 Drawing Figure(s); 8 Drawing Page(s)	
LINE COUNT:	1392	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB **Gel**-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a **gel** on a tissue surface *in vivo*. The **gels** formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 4 OF 5 USPATFULL on STN

ACCESSION NUMBER: 2001:36912 USPATFULL

TITLE: Multiblock biodegradable hydrogels for drug delivery and tissue treatment

INVENTOR(S): Pathak, Chandrashekhar P., Lexington, MA, United States  
Barman, Shikha P., Bedford, MA, United States  
Philbrook, C. Michael, Boston, MA, United States  
Sawhney, Amarpreet S., Lexington, MA, United States  
Couri, Arthur J., Boston, MA, United States  
Avila, Luis Z., Arlington, MA, United States  
Kieras, Mark T., Burlingame, CA, United States  
Focal, Inc., Lexington, MA, United States (U.S.)

corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 6201065	B1	20010313
APPLICATION INFO.:	US 1996-692914		19960726 (8)
DOCUMENT TYPE:	Utility		
FILE SEGMENT:	Granted		
PRIMARY EXAMINER:	Yoon, Tae		
LEGAL REPRESENTATIVE:	Arnall Golden & Gregory, LLP		
NUMBER OF CLAIMS:	28		
EXEMPLARY CLAIM:	1		
NUMBER OF DRAWINGS:	16 Drawing Figure(s); 8 Drawing Page(s)		
LINE COUNT:	1517		

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a crosslinkable group are provided. The macromers can be covalently crosslinked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

L3 ANSWER 5 OF 5 EPFULL COPYRIGHT 2005 EPO/FIZ KA on STN

ACCESSION NUMBER: 2003:149942 EPFULL  
ENTRY DATE PATENT: 20050223  
ENTRY DATE PUBLICATION: 20050223  
UPDATE DATE PUBLICAT.: 20050223  
DATA UPDATE DATE: 20050223  
DATA UPDATE WEEK: 200508  
TITLE (ENGLISH): Wrapping material for seamless capsules  
TITLE (FRENCH): Materiau d'enrobage pour gelules sans soudure  
TITLE (GERMAN): Huellmaterial fuer nahtlose Kapseln  
INVENTOR(S): Voigt, Ines, Reismuehle 20, 22087 Hamburg, DE;  
Schleifenbaum, Birgit, Route de la Versoix 5, 1299  
Crans pres Celigny, CH; Aickele, Frank, Weisse Breite  
15, 37603 Holzminden, DE  
PATENT APPLICANT(S): Symrise GmbH & Co. KG, Muehlenfeldstrasse 1, 37603  
Holzminden, DE  
PATENT APPL. NUMBER: 4476030  
AGENT: Eisenfuehr, Guenther, Dipl.-Ing., Eisenfuehr, Speiser &  
Partner Patentanwaelte Rechtsanwaelte Postfach 10 60  
78, 28060 Bremen, DE  
AGENT NUMBER: 3301  
LANGUAGE OF FILING: German  
LANGUAGE OF PUBL.: German  
LANGUAGE OF PROCEDURE: German  
LANGUAGE OF TITLE: German; English; French  
DOCUMENT TYPE: Patent  
PATENT INFO TYPE: EPA1 Application published with search report  
PATENT INFORMATION:

	NUMBER	KIND	DATE
DESIGNATED STATES:	EP 1508591	A1	20050223
	AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LI		
	LU MC NL PT RO SE SI SK TR		
APPLICATION INFO.:	EP 2003-19044	A	20030822
PRIORITY INFO.:	EP 2003-19044	A	20030822 *

ABEN

Composition for use as a sheathing material for the production of seamless capsules comprises agar, a hydrolyzed starch having a viscosity of less than 50 mPas and water

A composition (I) for use as a sheathing material for the production of seamless capsules (II) comprising a liquid core and an encapsulating sheath comprises: (a) 1.5-4 weight% agar; (b) 10-22 weight% of a hydrolyzed starch having a viscosity of less than 50 mPas (measured as a 15 weight% aqueous solution at 80 degreesC); (c) 70-85 weight% water and optionally other additives. Independent claims are included for: (1) a seamless capsule (II) having a sheath comprising the composition (I); (2) a process for the production of the capsules (II) by preparation of a liquid core, preparation of the composition (I) with simultaneous extrusion of the core and composition (I) through inner and outer nozzles such that droplets having a liquid core and sheath form followed by hardening of the sheath with optional drying.